{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"description":"A biomarker reduction was any decrease from baseline in ctDNA and/or serum tumor antigen levels (CA19-9 or CEA).","groups":[{"description":"The ctDNA Group included subjects with detectable ctDNA at baseline.","id":"OG000","title":"ctDNA Group"},{"description":"The Serum Tumor Biomarker Group included subjects who did not have detectable ctDNA at baseline, but did have either detectable CA19-9 or CEA.","id":"OG001","title":"Serum Tumor Biomarker Group"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All enrolled subject by biomarker type at baseline","reportingStatus":"POSTED","timeFrame":"6 months","title":"The Proportion of Participants With Biomarker Reduction by Biomarker Type","type":"SECONDARY","unitOfMeasure":"Participants"}